Narnatumab

Narnatumab (pronunciation: nar-na-tu-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a type of biological therapy that targets and sticks to specific proteins on the surface of cancer cells.

Etymology

The name "Narnatumab" follows the INN naming convention for monoclonal antibodies, with the "-mab" suffix indicating it is a monoclonal antibody. The "narna" prefix does not have a specific meaning in the INN system.

Mechanism of Action

Narnatumab works by binding to specific proteins on the surface of cancer cells. This binding can trigger the immune system to attack and destroy the cancer cells. The specific proteins that Narnatumab targets are still under investigation.

Related Terms

• Monoclonal Antibody
• Biological Therapy
• Cancer
• INN
• Immune System

See Also

• List of Monoclonal Antibodies
• Cancer Treatment

External links

• Medical encyclopedia article on Narnatumab
• Wikipedia's article - Narnatumab

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski